Article Information
History
- September 27, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- David Baker1,*,
- Amy MacDougall2,
- Angray S. Kang1,3,
- Klaus Schmierer1,5,
- Gavin Giovannoni1,5 and
- Ruth Dobson4,5,*
- 1The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom
- 2Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom
- 3Centre for Oral Immunobiology and Regenerative Medicine, Dental Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 4Preventive Neurology Unit, Wolfson Institute of Population Health, Barts and The London School of Medicine & Dentistry Queen Mary University of London, London, United Kingdom
- 5Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
- ↵*Correspondence: ruth.dobson{at}qmul.ac.uk/david.baker{at}qmul.ac.uk
Posted September 27, 2021.
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
